azathioprine / Generic mfg. - LARVOL DELTA

BH20 A multicentre analysis of the adequacy of alopecia horizontal biopsy samples over 10 years. (PubMed, Br J Dermatol) - "Twenty-six patients had received either topical steroids, minoxidil, spironolactone, tamoxifen, contraceptive pill, azathioprine or ketoconazole shampoo. We recommend using a standardized alopecia request form with clinical data and duration of onset, avoiding biopsies for very early or very late-onset disease of > 4 years, and inserting a follicular analysis table within the report to compare with the normal standard values, to improve the diagnostic outcome. Combining the use of digital pathology with artificial intelligence in the future may increase the diagnostic accuracy."

Journal • Retrospective data • Acne Vulgaris • Alopecia • Atopic Dermatitis • Breast Cancer • Chronic Kidney Disease • CNS Disorders • Crohn's disease • Depression • Dermatology • Dermatomyositis • Dermatopathology • Diabetes • Endocrine Disorders • Gastroenterology • Genetic Disorders • Immunology • Inflammatory Arthritis • Inflammatory Bowel Disease • Lupus • Metabolic Disorders • Mood Disorders • Multiple Sclerosis • Myositis • Oncology • Polycystic Ovary Syndrome • Psoriasis • Psychiatry • Renal Disease • Rheumatology • Sjogren's Syndrome • Solid Tumor • Systemic Lupus Erythematosus • Urticaria

Evaluation of TPMT and NUDT15 Testing in the Clinical Management of Azathioprine Therapy (ASHP 2025) - No abstract available

Clinical • NUDT15

Daratumumab for immune-mediated thrombotic thrombocytopenic purpura (iTTP): Results from the international, multicenter darttp study (ASH 2025) - "Patients had received a median of 3 (IQR 2)previous IST, including rituximab (100%), bortezomib and mycophenolate (25% each), cyclosporine andcyclophosphamide (20% each), azathioprine (15%), vincristine (10%), obinutuzumab, ofatumumab, andsplenectomy (5% each). Seventeen patients received daratumumab in the remission phase (i.e., forADAMTS13 relapse or intolerance to other IST), while 3 during an acute episode (plasma-based therapyand caplacizumab ongoing in 3 and 2 patients, respectively)...Disease duration, previous IST used, daratumumab schedule, ordemographics did not correlate with response or its duration...A patient not receiving acyclovir had a grade 2 zoster skininfection 3 months after her last daratumumab infusion. in this study, daratumumab warranted rapid ADAMTS13 remission in 75% of iTTP patientsrefractory or intolerant to rituximab and other conventional IST... in this study, daratumumab warranted rapid ADAMTS13 remission in 75% of iTTP patientsrefractory..."

Clinical • Cardiovascular • Dermatology • Hematological Disorders • Herpes Zoster • Thrombocytopenic Purpura • CD20

Azathioprine for the treatment of early Parkinson's disease (AZA-PD): a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial. (PubMed, Lancet Neurol) - P2 | "Azathioprine was well-tolerated in this population; however, the primary outcome was not met. Exploratory analyses suggested effects of azathioprine on peripheral and central immune biomarkers and on motor symptoms. Potential clinical effects could be greater in females than males, warranting further exploration."

Clinical • Journal • P2 data • CNS Disorders • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Movement Disorders • Parkinson's Disease

Exploring immunomodulation with azathioprine in Parkinson's disease. (PubMed, Lancet Neurol) - No abstract available

Journal • CNS Disorders • Immunology • Movement Disorders • Parkinson's Disease

Azathioprine Ameliorates Cellular Senescence in Rhabdomyolysis-Induced Acute Kidney Injury by Inhibiting the Vav1/Rac2/NF-κB Pathway in Macrophages. (PubMed, Eur J Pharmacol) - "Activation of macrophage Vav1/Rac2/NF-κB signaling promotes tubular cell senescence, whereas azathioprine counteracts this process by inhibiting the pathway."

Journal • Acute Kidney Injury • Chronic Kidney Disease • Nephrology • Renal Disease • CDKN1A • LMNB1 • RAC2 • VAV1

Erosive Lichen Planus With Ocular Involvement: A Case Report. (PubMed, Am J Case Rep) - "The patient received azathioprine (100 mg/day) and a short course of oral corticosteroids, which resulted in substantial improvement of ocular inflammation, mucocutaneous lesions, and visual acuity within 4 months...Ophthalmologists play a key role in recognizing systemic inflammatory disorders and coordinating interdisciplinary care. Prompt diagnosis, long-term follow-up, and systemic immunosuppressive therapy are vital to prevent scarring and permanent sequelae."

Journal • Cataract • Conjunctivitis • Dermatology • Dermatopathology • Gastrointestinal Disorder • Hepatitis C • Immunology • Infectious Disease • Inflammation • Keratitis • Lichen Planus • Mucositis • Ocular Infections • Ocular Inflammation • Ophthalmology

Consensus recommendations for the diagnosis and management of neuromyelitis optica spectrum disorder: A Saudi expert panel review. (PubMed, Mult Scler Relat Disord) - "This expert consensus provides evidence-based guidance for the diagnosis and management of NMOSD in Saudi Arabia, striking a balance between clinical evidence and expert opinion where data gaps exist. It emphasises individualised care, antibody testing, and long-term immunosuppressive strategies while highlighting the need for further research on treatment duration and failure criteria."

Journal • Review • CNS Disorders • Immunology • Multiple Sclerosis • Neuromyelitis Optica Spectrum Disorder • Rare Diseases

Prognosis After Discontinuation of Azathioprine or Mycophenolate Mofetil in Well-Controlled Myasthenia Gravis: A Retrospective Analysis. (PubMed, Muscle Nerve) - "The results of this study suggest that patients in PR are less likely to relapse compared to those in MM 1. In well-controlled MG patients, AZA/MMF may be discontinued."

Journal • Retrospective data • CNS Disorders • Myasthenia Gravis

In-silico, in-vitro, and proteomics analyses on repurposed drugs in targeting the small GTPase, Rho subfamily protein (Rho GTPase), and putative Rho GTPase-activating protein (RhoGAP) of Giardia lamblia. (PubMed, J Genet Eng Biotechnol) - "Giardia lamblia is a globally prevalent protozoan responsible for Giardiasis, an intestinal disease commonly treated with nitroimidazoles such as metronidazole, tinidazole, and albendazole...Target sequence analysis revealed Dextromethorphan and Azathioprine as candidate Rho GTPase inhibitors, and Imatinib, Dasatinib, and Ponatinib as RhoGAP inhibitors...These findings highlight RhoGAP as a promising therapeutic target in G. lamblia, with Dasatinib showing potential as a repurposed treatment for Giardiasis. Proteomic data are publicly available in the MASSIVE database under identifier MSV000097321."

Journal • Preclinical • Gastrointestinal Disorder • Infectious Disease

Thiopurine pharmacogenomic landscape in India: TPMT and NUDT15 allele frequencies (ASH 2025) - "Thiopurines—such as azathioprine, mercaptopurine, and thioguanine—are commonly used in hematology as immunosuppressants and chemotherapeutic agents. We also identified rare, potentially deleterious TPMT variants that are absent or underrepresented in global reference datasets, underscoring the value of population-specific pharmacogenomic profiling. Our findings support pre-treatment NUDT15 genotyping (and TPMT where indicated) with genotype-informed dose adjustment and early monitoring to reduce myelosuppression-related treatment interruptions."

Biomarker • NUDT15

Risk of lymphoma with antimetabolite and biologic combinations: A pharmacovigilance analysis using the FDA adverse event reporting system database (ASH 2025) - "Our study compared combinations of antimetabolites—such asmethotrexate (MTX), mercaptopurine (6-MP), and azathioprine (AZA)—with anti-TNF agents includinginfliximab, adalimumab, certolizumab, and golimumab, to determine which regimens were most stronglyassociated with lymphoma. Clinicians should carefully weigh the risks and benefits of combination immunosuppressivetherapy, especially when prescribing infliximab with MTX or 6-MP, given the observed synergistic increasein risk for lymphoma."

Adverse events • Hematological Malignancies • Immunology • Lymphoma • ROR1

Preliminary clinical experience with mesenchymal stromal cells in autoimmune hemolytic anemia: A Case series in two dogs and one cat (ASH 2025) - "While first-line therapy typically consists of corticosteroids in combination with adjunctive immunosuppressiveagents such as cyclosporine or azathioprine, a subset of patients fails to achieve sustained clinicalremission. However, further controlled clinical trials arewarranted to confirm efficacy, optimize dosing regimens, and comprehensively evaluate long-term safetyprofiles. Given the shared pathophysiology of AIHA across species, these data may provide importanttranslational insights relevant to the development of MSC-based therapies for human autoimmunehemolytic conditions."

Clinical • Stroma • Anemia • Autoimmune Hemolytic Anemia • Hematological Disorders • Immunology • Infectious Disease • CD44 • ITGB1 • THY1

Propensity score matching analysis comparing the efficacy and long-term outcomes of belumosudil to the best available treatment as a historical control, used as second-line therapy or beyond for chronic GVHD after steroid failure. (ASH 2025) - "Treatment included prednisone in 284 (92.5%),mycophenolate in 145 (47.2%), azathioprine (AZA) in 144 (46.9%), a calcineurin inhibitor in 54 (17.6%),hydroxychloroquine in 51 (16.6%), extracorporeal photopheresis in 20 (6.5%), and rituximab in 10 (3.3%).A propensity score was calculated from the following unbalanced clinical factors: age (≥60 vs. <60), GvHDseverity (severe vs. mild/moderate), HCT-CI score (≥3 vs. <3), and treatment line (≥4th vs. <4th). The BEL group showed 72.0% [55.0–83.4] 12 months' FFS rate vs25.3% [10.6–43.1] for BAT (p<0.001), whereas 12 months' OS rates were 92.1% [77.3–97.4] and 88.4%[60.8–97.0] (p=0.317), respectively.Both univariate (UVA) and multivariate analysis (MVA) (BEL vs. BAT, HCT-CI ≥3, severe cGvHD, age ≥ 60,and previous acute GvHD) for FFS confirmed BEL superiority over BAT (hazard ratio (HR) 0.288 [0.155–0.535], p<0.001; no differences for the other factors). For OS, UVA showed that BEL had a trend for ahigher OS..."

Clinical • Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology

A US real-world analysis of demographics, transplant patterns, and survival outcomes in posttransplant lymphoproliferative disorder (PTLD) (ASH 2025) - "Other agents includedprednisone (6.2%), cyclosporine (5.8%), sirolimus (5.8%), dexamethasone (4.8%), azathioprine (3.1%),methylprednisolone (1.9%), everolimus (0.7%), ibrutinib (0.6%), ruxolitinib (0.6%), mycophenolate(0.3%), basiliximab (0.2%), and thymoglobulin (0.1%).Extranodal, bone marrow, and CNS involvement were present in 29.5%, 1.9%, and 1.8% of cases,respectively...Median OSfor heart transplant recipients was 2730 days, and for those who underwent HSCT, 2643 days.Regarding treatment, only 10 patients received bispecific antibodies (glofitamab, epcoritamab, ormosunetuzumab) and only 23 patients received CAR-T therapy. This study represents one of the largest real-world analyses of PTLD in adult patients inthe US, utilizing the TriNetX dataset spanning over three decades. This study represents one of the largest real-world analyses of PTLD in adult patients inthe US, utilizing the TriNetX dataset spanning over three decades. Improvement in OS in more recentyears..."

Clinical • Post-transplantation • Real-world • Real-world evidence • Bone Marrow Transplantation • Epstein-Barr Virus Infections • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Solid Organ Transplantation • Transplantation

Real world outcomes of patients with cold agglutinin disease (ASH 2025) - "The median number of 1 (range 0-7) lines of therapy for CAD were administered.Rituximab monotherapy ± plasma exchange were most frequently employed (n=31) and, along withdexamethasone-rituximab-cyclophosphamide (n=7), achieved the highest response rates of 71% (22/31and 5/7, respectively). Bortezomib combinations yielded a 67% response (2/3), as did R-CHOP-likecombinations (4/6). Complement inhibitors were used in 13 patients with a 61% response rate (8/13).Bendamustine-rituximab, BTKi, and daratumumab each demonstrated response rates of 57% (4/7 each),while venetoclax produced a 50% response (1/2). Among 54 patients with CAD, many required multiple treatment regimens. Response rates exceeded 50%in the majority with best responses with traditional rituximab-based therapies and efficacy with cloneand complement-directed therapy."

Clinical • IO biomarker • Real-world • Real-world evidence • Autoimmune Hemolytic Anemia • Cardiovascular • Complement-mediated Rare Disorders • Hematological Disorders • Hematological Malignancies • Lymphoma • Lymphoplasmacytic Lymphoma • Non-Hodgkin’s Lymphoma • Thrombosis • Waldenstrom Macroglobulinemia

Prevalence and demographics of autoimmune hemolytic anemia in the United States (ASH 2025) - "Annual prevalence was stratified by age group, sex,and prescription fill for an AIHA-related treatment (systemic steroids, immunosuppressants[azathioprine, mycophenolate, cyclosporin, cyclophosphamide, danazol, bortezomib, rituximab],splenectomy) in the calendar year. AIHA prevalence in this study was consistent with estimates from European countries andhas been increasing in recent years, providing evidence of consistent disease epidemiology across severalgeographies."

Anemia • Autoimmune Hemolytic Anemia • Hematological Disorders • Immunology

Real-world effectiveness and safety of fostamatinib in difficult-to-treat patients: Results of a three-year registry in France. (ASH 2025) - "Seventy-height percent ofpatients had been exposed to eltrombopag, 74.4% to romiplostim, 86.0% to rituximab, 48.8% tomycopenolate or azathioprine, and 28.0% were splenectomized. Fostamatinib was used in previously very heavily treated patients, with response rates of44.0% at M3 and of 20.0% at M24. Combination therapy with TPO-RA is an option to consider in thispopulation. No new safety signal was observed."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Hematological Malignancies • Immune Thrombocytopenic Purpura • Immunology • Infectious Disease • Lymphoma • Musculoskeletal Diseases • Myocardial Infarction • Neutropenia • Pulmonary Arterial Hypertension • Thrombocytopenia • Thrombocytopenic Purpura • Thrombosis

Severe hemolysis flare of refractory warm hemolytic anemia with positive complement component C3d responsive to iptacopan with cyclophosphamide and prednisone (ASH 2025) - "All patients had received at least two prior therapies, including but not limited to steroids,IVIG, rituximab, tacrolimus and azathioprine without achieving a good response...In addition, twopatients (13.33%) had a history of bortezomib treatment, and another two patients (13.33%) hadreceived azathioprine therapy... Refractory wAIHA patients achieved good therapeutic efficacy after treatment with Iptacopancombined with cyclophosphamide and prednisone. Our clinical practice will provide a new potentialapproach to the treatment of refractory wAIHA."

Anemia • Autoimmune Hemolytic Anemia • Hematological Disorders • Hematological Malignancies • Immunology • Inflammatory Arthritis • Lupus • Lymphoma • Systemic Lupus Erythematosus

Hematological symptom burden and treatment patterns in patients with IgG4-related disease: A real-world, multicenter retrospective analysis (ASH 2025) - "The most used agents includedrituximab (6%), azathioprine (6%), mycophenolate mofetil (5%), and methotrexate (3%).In this large, real-world cohort of patients with IgG4-RD, hematologic manifestations were observed inover one-fifth of patients and were associated with a numerically higher mortality rate.Lymphadenopathy was the most common hematologic feature. In this large, real-world cohort of patients with IgG4-RD, hematologic manifestations were observed inover one-fifth of patients and were associated with a numerically higher mortality rate.Lymphadenopathy was the most common hematologic feature. Despite the widespread use ofcorticosteroids, a substantial proportion of patients required steroid-sparing agents. These findingshighlight the hematologic complexity of IgG4-RD and underscore the need for multidisciplinarymanagement and prospective studies focused on hematologic outcomes."

Real-world • Real-world evidence • Retrospective data • Cardiovascular • Eosinophilia • Hematological Malignancies • Hepatology • Hypertension • Inflammation • Monoclonal Gammopathy

Double or triple therapy in newly diagnosed immune thrombocytopenia: Improving outcomes from the west-central Mexican experience. (ASH 2025) - "Treatment consisted of oral or IV dexamethasone 40mg daily for 4 days every 21 days for two cycles; eltrombopag 50 mg daily for 28 days, suspended ifplatelet counts rise above 400x109/L; and azathioprine 2 mg/kg/day for 42 days in DEA arm. With this latter group the DOR was better at 180 and maintained at 360 days.The cornerstone in the treatment has been with steroids, but differences in type of steroid and number ifcycles remain unanswered, even more with combinations, and the Introduction of new agents (BloodReviews 2025,101300). Multicentric clinical trials are needed to evaluate the combined therapy that willbring long lasting complete remissions or even cure in the first line of therapy."

Immune Thrombocytopenic Purpura • Immunology • Infectious Disease • Thrombocytopenia • Thrombocytopenic Purpura

Calcineurin inhibitors reduce risk of MGUS progression to multiple myeloma in immunosuppressant users: A retrospective multi-institution cohort study (ASH 2025) - "To ensure maximal consistency across the studied population,both the exposure group and the control group had received at least one of the following IST—azathioprine, leflunomide, cyclophosphamide, methotrexate, sulfasalazine, or mycophenolate mofetil—within 1 year prior to, or any time after, the initial diagnosis of MGUS but before any diagnosis of MM.Patients in CNi group were defined by additional CNi exposure (excluding topical and ophthalmic route)within the same time window, whereas control had never received CNi. These findings support thehypothesis that dampening immune activation may lower the risk of malignant transformation in MGUS.Clinically, this study alleviates concerns regarding the potential oncogenic risks of cytotoxic T cellsuppression in patients with coexisting autoimmune disorders and MGUS. Furthermore, it raises thepotential role of T cell inhibitors as one of the interventions to prevent MGUS progression in broaderpatient populations, warranting..."

Retrospective data • Amyloidosis • Chronic Kidney Disease • Hematological Malignancies • Immunology • Monoclonal Gammopathy • Multiple Myeloma • Nephrology • Ophthalmology • Renal Disease • Solid Organ Transplantation • CD8 • GZMB

Heterogeneity of treatment regimens and related health resource use in managing patients with waiha: A US multi-database retrospective observational Study (ASH 2025) - "Patients on treatment were defined by use of oral corticosteroids (OCS), immunosuppressants(IST) (including azathioprine, mycophenolate mofetil, cyclosporine, cyclophosphamide, or tacrolimus) orrituximab. No changes in rescue treatments, and anincrease in blood transfusions after rituximab infusion suggest treatment gaps remain. Analysis revealsheterogeneity in rituximab dosing patterns including high deviation from standard dosing practices; thisvariance from published expert opinion along with common use of rescue therapies suggests continuedneed for standardized guidelines and development of targeted therapies in wAIHA."

Heterogeneity • Observational data • Retrospective data • Autoimmune Hemolytic Anemia • Hematological Malignancies • Immunology • Solid Tumor

Anti-CD19 chimeric antigen receptor T-cell therapy for patients with non-Hodgkin's lymphoma and concurrent autoimmune disease (ASH 2025) - "methotrexate, hydroxychloroquine (HCQ),azathioprine); 9 required biologic/targeted DMARD (ex. adalimumab, etanercept, risankizumab,infliximab, rituximab).DMARDs were weaned prior to CART however 9 pts (37.5%) remained on AID tx at the time of cellcollection, including HCQ (n=4), sulfasalazine/mesalamine (n=2), and 1 each of prednisone, colestipol,sulfasalazine, and apremilast... In this single center study of pts receiving CART for NHL we found no difference in responserates nor survival outcomes in pts with or without AID and therefore propose that AID should notpreclude the use of CART. Lower severity of ICANS was seen in AID pts, though additional study withlarger cohorts is required. The majority of pts were able to taper off AID tx prior to CART, while HCQ wasable to be safely continued throughout CART collection with no apparent effect on CART efficacy."

CAR T-Cell Therapy • Clinical • Ankylosing Spondylitis • B Cell Non-Hodgkin Lymphoma • CNS Disorders • Dermatology • Dermatomyositis • Gastroenterology • Hematological Disorders • Hematological Malignancies • Immunology • Inflammatory Arthritis • Lymphoma • Myasthenia Gravis • Myositis • Non-Hodgkin’s Lymphoma • Psoriasis • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies

P062 National clinical reaudit on managing adults with bullous pemphigoid 2024: shifting clinical practices. (PubMed, Br J Dermatol) - "The use of doxy-cycline as first-line treatment rose significantly (83.8% in 2024 vs. 50.7% in 2018, P < 0.001), while azathioprine was less frequently prescribed, reflecting a shift towards mycophenolate mofetil. The continued reliance on oral corticosteroids despite increased doxycycline use suggests caution in transitioning to safer options. These findings emphasize the need for updated BP management guidelines and targeted educational initiatives to support best practice."

Journal • Bullous Pemphigoid • Dermatology • Dermatopathology • Immunology • Infectious Disease • Novel Coronavirus Disease • Osteoporosis • Rheumatology